Full Press Release Details
Okay, welcome everybody to Wall Street Reporters' Next super stock
live stream, where we bring you those stocks, which have that 10 x to 100 x upside potential companies going up to massive multi-billion
dollar market opportunities that are at a key inflection point right now, and with multiple catalysts in place. Uh, and that perfectly
describes Aditxt. I should also add Aditxt is, uh, at a great valuation right now, which is another thing that we look for. We like stocks
that are what we call asymmetric setups, where you have a cheap valuation. I think Aditxt is trading at $5 million market cap today, which
is incredibly cheap. And multiple shots on goal for. You know, these are potentially short term, could be a hundred million dollars opportunities
with these spin outs. So, uh, with that said, Amro, welcome back to the program,
Amro Albanna (01:15):
Jack. How you doing? Thanks for having me again.
Absolutely. So Amro, so, so what we've been trying to do in the last,
over the last couple of videos is really help investors to better understand the Aditxt story. Because I think the reason the opportunity
for investors, and the reason why the stock is cheap is, you know, a lot of, I think, I think the market doesn't quite understand the
business model. You know, you have, you have a couple of different operating units in the company. So, as you know, as people understand
the, the investment thesis as they understand your, your business better, I think the stock should be trading at a much higher valuation.
cause, again, based on what you have, you know, the comps in your space would be, you know, 10 x higher. Like literally, this stock would
be trading at, you know, 12 bucks, a 12 bucks a share if people understood it.
So last week we spoke about the Pearsanta, which is, uh, a, uh, an
operation or subsidiary that you were spinning out. It's the Cancer Detection Unit. Uh, today, uh, we're gonna be talking about Adimune,
uh, which is your, your, um, the autoimmune disorder, the, you know, the biotech business that you have, you know, uh, developing treatments
for, uh, autoimmune disorders. Next week we're gonna have a, uh, was it, uh, Adifem? Everything was an, was an A. So Adifem is, uh, is
next week. So these are the three subsidiaries that you have. Uh, and yeah, as I mentioned earlier, uh, you know, each of these, you know,
each of these you've acquired, or one of them you are in the process of acquiring. And I think, as you've explained last, and I, I want
you to maybe, uh, talk about, about a little bit more today is the idea is you acquire these, these, uh, assets. You, uh, build value,
you add value, you build them up, and then you monetize em, whether through a potential IPO spin out, et cetera. But the idea is to create
value for the Aditxt shareholders. I mean, no. So, so far,
Amro Albanna (03:08):
Jack, I do, I really do look forward to these calls, uh, at least,
you know, for now having them weekly, because it is gonna be critical for us and for our success and for all stakeholders that, you know,
people will begin to understand what Aditxt is. You know, are we a women's health company? Are we an autoimmune company? Are we a cancer
detection company? It's important for our stakeholders and current and potential shareholders to truly understand what is the business
model? What is the value proposition, right? So generally speaking in biotech, we all understand that biotech, you know, as, as an industry,
as a field, um, represents great opportunities. But it also comes with great challenges. We all understand the concept of a young company
in biotech that is working on a technology innovation molecule where if it's successful, it's a massive opportunity. But we all understand
also the failure and the probability of failure that comes with that.
That's just biotech in general. The, you know, the approach by Aditxt
is fundamentally different. You know, we believe having a publicly owned platform that goes out and really looks for these potential opportunities
to address some of our most pressing health challenges, where we bring it in, build it, and capitalize on the opportunity at the right
time, is what Aditxt is all about. So it provides, you know, obviously some diversification inherently in the business model. Of course,
it comes with its own challenges, but really what Aditxt is, we go out, we, we look for these opportunities for these assets, for these
promising opportunities, whether it's about early detection of cancer autoimmunity, which we'll talk about today, women's health. And
the, the, the plan here is, again, we acquire em, we build them, we position for global commercialization opportunities, and we capitalize
Um, you know, whether it's through an IPO A spinoff sale, you know,
all the various options. So that's Aditxt and that's, that's really important for, you know, for, you know, uh, people that are watching
today or people that are gonna be watching this in the future for us to continue reiterating the business model so you, they understand
what a, B, C stands for, acquire, build, capitalize. And that's, that's where we are now as far as our market cap look, as a co-founder
and CEO of the company, of course, look, I, you know, I can't possibly say that, you know, that the market cap is in sync with our potential.
You know, I can't, you know, now the, you know, certainly we have to repeat, if you're a shareholder or if you are thinking of buying
the stock, you have to do your own due diligence. We're not gonna give guidance. We're not gonna tell you what the stock could be up,
down. That's really not the point. But the point is, right now, we are still a young microcap company, and we certainly believe that,
you know, upon the success of at least one of our programs, the goal here is to reflect on the over overall success of Aditxt, and it
becomes a catalyst for more innovations to acquire, to build and capitalize. And that's kind of the background of Aditxt.
Yeah. And, and I think, I think, again, this is, this is the exciting
part about this is that, you know, you have, you know, a Aditxt, again, I I keep calling it a unicorn farm. I hope it does. You don't,
you don't mind. But you know, the unicorn, in case anybody doesn't know, is a, uh, a startup company that becomes valued at a billion
dollars, just saying, just in case somebody is not familiar with the term. So you have this unicorn farm where you, you grow these unicorns.
Each of these, again, you have multiple shots on gold between, uh, add between, was it Adimune, Adifem, uh, and Pearsanta. Uh, each of
these, um, could be, for example, with Pearsanta, which is right now you have plans to, uh, spin that out, as, you know, as an IPO. Yeah,
that could be valued. I think, uh, there's been talk of a hundred million plus as a standalone public company.
And you know how that reflects back on Aditxt, what it means for the
Aditxt shareholders is, let's say, you know, you were paying 60% of that, which is, you know, most likely, right? So that means if that
thing is trading at a hundred million, Aditxt would be worth 60 million just from Pearsanta alone. So, which is basically a, a 12 x from
where the stock is right now, maybe even a little bit higher. So, and, and you have two more of those, you know, shots on goal with, with,
with Adimune, uh, with Adifem. Uh, so, and again, Adifem is the, uh, that's the women's health business that you are in the process of
acquiring. We're gonna talk about it next week in detail, but they're doing, uh, if I'm not mistaken, $20 million in revenues. And there's
a, there, there's, again, I think you have, uh, a number of ways to, uh, increase, uh, increase the, the, the growth rate dramatically
under the, uh, Aditxt umbrella.
So, and that could be also another spin out at some point worth what's
called five x revenues, which is, that's, that's pretty normal in the, you know, in the healthcare space, five, 10 times revenues for
something that's growing, uh, fast, maybe even more. So that's another a hundred million plus exit, uh, for, uh, for Aditxt. So, uh, now,
you know, Adimune, which we're gonna find out about in a couple minutes, we're gonna show the deck. Uh, and, but Adimune, let's say that's
another a hundred. So you have these a hundred million dollar plus short term or near term, uh, potential exits, which is, I think, very
exciting. Now, when I said billion dollar potential, yeah, down the road, these things potentially have, you know, the, you know, the
opportunity to become, you know, who knows where, where, where they can grow. Look, we've had stocks, we've introduced stocks on this
program at a dollar, you know, that ended up going to, you know, $800 a share, like, you know, axon, you know, nobody believed Axon, I
think it was a dollar 20, excuse me, you know, which made the tasers. And that became a 800, I think maybe actually 1500 up, because I
think they did split. So you never know how big these, these things can grow, these unicorns. So, um, with that said, uh,
Amro Albanna (09:19):
And from our, and from our view, Jack, and look, of course, look, I
think, you know, as I, you know, people ask me what the stock could be, you know, we don't really, you know, we really don't. And I don't,
certainly, we as a company do not provide any guidance what the, and frankly, the company wouldn't know. I mean, market conditions, shorts
long, all that stuff, right? A lot of dynamics. But here is what I would, here is what I would say, you know, from our point of view,
you know, when we're talking about the potential, look, again, I will repeat over and over again. There's always risk. Take a look at
the filings, all the this all the stuff, you know, just biotech is biotech, startups are startups. They come with all challenges. And
I'll always repeat that. cause people need to understand. That's just that, that just the journey of advancing innovations, it comes
We gotta put that aside and talk about when it comes to quantifying
the opportunity, rather, you know, from our point of view, let's talk about cancer detection. And I'm sure some of the people that were
not on the call, or, you know, last time when you're talking about cancer detection and when we're talking about, you know, 70%, um, I
believe it was, you know, when, when you talk about early detection of cancer and 70% get detected too late, we all understand the value
of early detection of cancer. Now, who, amongst us directly or indirectly, who hasn't been affected by cancer or heard the word cancer,
people understand the magnitude of the challenge when it comes to cancer. So with Pearsanta, we're starting and we're focused on early
detection of cancer as truly a way to address cancer. So rather than waiting for therapeutics, let's truly also focus on early detection
of cancer, and we're starting with prostate cancer.
So when you're talking about that field, look, everyone can begin to
evaluate the opportunity when it comes to some something as big as as cancer. So that's just Pearsanta. Today we're talking about autoimmunity,
and whether it's type one diabetes or psoriasis or multiple sclerosis or stiff person syndrome, there are about 80 to a hundred different
autoimmune conditions. Okay? Uh, you know, similar to the field of oncology, you know, who amongst us hasn't heard of type one diabetes,
either directly or indirectly, or psoriasis, or, you know, or stiff person syndrome, or multiple sclerosis, or, or, or, or, so when it
comes to autoimmunity is another big health challenge, is another big health challenge that we founded Adimune as a subsidiary of Aditxt
to go after that disease in a very unique approach, similar to what Pearsanta is doing when it comes to cancer and oncology. And that's,
you know, and that's really a way to evaluate for every individual who's watching us, reading about us, reading our websites, reading